UAE's Crescent Enterprise joins US biotech firm's $55m series A

CE-Ventures participated in a US$55 million series A funding round for Think Bioscience, a US-based biotech firm developing small-molecule drugs for difficult targets.

CE-Ventures, the venture arm of Crescent Enterprises, backs biotech ventures with R&D-led models.

The oversubscribed round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors, with CE-Ventures among other participants.

The funding will support Think Bio’s pipeline of drug programs and its synthetic biology platform, which seeks to identify new binding sites on proteins previously considered undruggable.

The company’s lead project targets genetic mutations linked to Noonan syndrome, a condition with no current targeted therapies.

🔗 Source: CE-Ventures

🧠 Food for thought

Implications, context, and why it matters.

Details on Think Bioscience’s Noonan syndrome program remain undisclosed

The specific genetic driver or drivers being targeted have not been identified in the available material 1.
Noonan syndrome has been linked to pathogenic variants across multiple genes. In a retrospective cohort study of 116 genetically confirmed Noonan syndrome patients, PTPN11 variants were most frequent at 68.1%, followed by SOS1 at 10.3% and RAF1 at 8.6%, with distinct genotype–phenotype correlations reported 2.
The drug candidate’s development stage, mechanism of action, and any supporting preclinical data have not been disclosed in the available material 1.
With those gaps, the program’s scientific risk and distance from clinical trials cannot be assessed. The lack of approved therapies that directly address the underlying biology of Noonan syndrome adds to that uncertainty 1.

New capital for ‘undruggable’ targets creates a picks-and-shovels opportunity

Lab-tech vendors and drug-discovery service firms may see more demand after Think Bioscience’s USD 55 million Series A, since synthetic biology and early-stage small-molecule work need specialized infrastructure 1.
Think Bioscience says its platform uses “high-throughput functional surveys,” which can drive spending on lab automation, cloud data management, plus contract research organization (CRO) services for preclinical work 1.
Investors can also track a wider pattern as startups like Topos Bio raise money to go after hard protein targets using other approaches, including AI-native platforms 3.
That backdrop supports a tools-first investment view focused on “picks and shovels” for small-molecule drug discovery. Mordor Intelligence estimates that market at USD 67.42 billion in 2026 4.